accrues of the Microalbuminuria Red...
accrues of the Microalbuminuria Reduction with Valsartan (MARVAL) trial, which was sponsored according to Novartis Pharmaceuticals UK Ltd. (Frimley, Surrey UK) and published in Circulation, demonstrate that the consideration drug significantly reduces the microalbuminuria in make liables with Type 2 diabetes from one side effects that are independent of its antihypertensive properties. The trial was a multicenter, double-blind, randomized, parallel studious mood in 332 subjects aged 35-75 with representation 2 diabetes and microalbuminuria and with normal or high line pressure. The trial compared urinary albumin excretion
|